Drug Profile
Research programme: psychiatric disorder therapeutics - Camino Pharma
Alternative Names: SBP 0069330Latest Information Update: 12 Dec 2023
Price :
$50
*
At a glance
- Originator Camino Pharma
- Developer Camino Pharma; Sanford Burnham Prebys Medical Discovery Institute; University of California, San Diego; Wake Forest University School of Medicine
- Class Antidepressants; Drug withdrawal therapies; Small molecules
- Mechanism of Action Metabotropic glutamate receptor 2 modulators; Metabotropic glutamate receptor 3 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alcoholism; Depressive disorders; Major depressive disorder
- No development reported Cocaine-related disorders; Smoking withdrawal